Company Overview and News
Estimates for Murphy Oil Corporation (MUR - Free Report) have been revised upward over the past 60 days, reflecting analysts’ optimism in the stock post solid first-quarter 2018 results. The Zacks Consensus Estimate for 2018 and 2019 earnings per share have moved up 45.4% and 41.3% to $1.41 and $1.30, respectively.
OAS CQP LNG CTLR MUR.WI MUR CLR
With oil price recovery taking hold, several U.S. oil and gas companies entered 2018 with a compelling plan - sell undeveloped or less essential fields and invest the money to boost returns from their sweetest, most productive spots.
BLT WLL BHPBF PVAYQ QEP DVN PVA OAS BHP PVAC BBL BHP BHPLF
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is Oasis Petroleum Inc.
Whiting Petroleum Corporation (WLL - Free Report) has been a preferred pick for investors lately. The shares of the company have rallied 76% over the past three months, while the stocks in this industry have collectively gained just 10%.
PVH OAS WLL WRD UTX GPRK
Estimates for Oasis Petroleum Inc. (OAS - Free Report) have been revised upward over the past 30 days, reflecting analyst’s confidence in the stock post solid first-quarter 2018 results. The Zacks Consensus Estimate for 2018 and 2019 earnings has been moved up 8.3% and 22.1% to 39 cents and 83 cents per share, respectively. The Houston, TX-based company is an independent exploration and production entity focused on acquisition and development of oil and natural gas resources.
APC OAS WRD BCEI AEUA
Energy Transfer Partners L.P.’s (ETP - Free Report) mega project, Dakota Access Pipeline, recently marked its one-year anniversary. Disregarding criticism from Native American tribes and environmental groups, the pipeline has been operational for a year now and proved to be a silver bullet for North Dakota’s economic potential. Clears Many Challenges The pipeline was supposed to become operational by the end of 2016.
ENBBF CHJHF HES PSX CTLR CHA ENB MPC HES.PRA ENB ETP OAS 0728 EBBNF CLR
The futures are trading slightly higher Monday morning as investors are hoping for another solid week like the one the markets produced last week, when both the NASDAQ and the Russell 2000 hit new all-time highs. With the second quarter starting to wind down, some of the companies that will be reporting in July could start releasing earnings warnings, so it pays to stay alert now.
SGEN PK WFCNP APA SPWR XEC DTE NXPI WFC.PRL 5GD DTJ WFC.PRJ COP WFC.PRT MTCH WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX KOS WFC.PRW WFC.PRV MO FRAC WFC WFC.WS OLN INCY SRGRF OAS DTW DTV FDC EEFT TRI SEMG DTY
Diamondback Energy Inc.’s (FANG - Free Report) strong foothold in the prolific Permian Basin has been quite a boon to the company’s performance for a while. Notably, the shares of this Texas-based upstream player have increased 30% over a year, outperforming the industry’s growth of 13.5%.
OAS CQP LNG MU LB OXY FANG
Oil prices surged on Jun 7, as investor concerns prevailed over an impending supply shortage from Iran, gradually declining output from Venezuela and a longer-term picture of tighter supply from OPEC (Oil and Petroleum Exporting Countries) and non-OPEC allies led by Russia. Notably, oil prices had plummeted on Jun 6, following the U.S. Energy Information Association (EIA) report that domestic crude has registered its lowest finish in almost two months for the week ended Jun 1.
APC OAS MU CVRR LB OXY GPRK AEUA
The company produced 76.8 thousand barrels of oil equivalent per day in the first quarter of 2018, representing an increase of 22% over the first quarter of 2017.
In Q1 2018, 12 hedge funds bought W&T Offshore (WTI) stock, and 23 hedge funds sold WTI stock. Thus, in Q1 2018, total selling hedge funds outnumbered total buying hedge funds by 11. As of March 31, 31 hedge funds held WTI in their portfolio. Out of these, only one hedge fund has WTI in its top ten holdings.
CRC OAS WLL
Stocks were up earlier this week, but fresh warnings that a North Korea summit might not actually happen in June weighed on the indexes on Wednesday. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
RIO CY RIO KOOL MS.PRE MS.PRF MS.PRG MS.PRA KOOLW AEE RTPPF EL SHAK CELG RTNTF MS VNRX CSCWF CELGZ WLL KMPH INTU OAS MS.PRI RIO MS.PRK VIRT TRI
4h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to OAS / Oasis Petroleum Inc. on message board site Silicon Investor.
as of ET